Reconstitution of circulating lymphocyte subsets after treatment with cladribine tablets in the 96-week CLARITY study in relapsing-remitting multiple sclerosis

被引：0
|
作者：
Sorensen, P. Soelberg
Rieckmann, P.
Comi, G.
Cook, S.
Giovannoni, G.
Rammohan, K.
Vermersch, P.
Bock, D.
Hamlett, A.
Fevr, T.
Musch, B.
Greenberg, S.
机构：
[1] Copenhagen Univ Hosp, Copenhagen, Denmark
[2] Bamberg Hosp, Bamberg, Germany
[3] Univ Vita Salute San Raffaele, Milan, Italy
[4] Univ Med & Dent, Newark, NJ USA
[5] Barts & London Queen Marys Sch Med & Dent, London, England
[6] Ohio State Univ, Columbus, OH 43210 USA
[7] Univ Lille Nord France, Lille, France
[8] Merck Serono SA, Geneva, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2010年 / 257卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P442
引用
收藏
页码：S143 / S143
页数：1
相关论文
共 50 条
  • [1] Effects of Cladribine Tablets on Circulating Lymphocyte Subset Reconstitution in the 96-Week CLARITY Study in Relapsing-Remitting Multiple Sclerosis (RRMS)
    Soelberg, Per
    Rieckmann, Peter
    comi, Giancarlo
    Cook, Stuart
    Giovannoni, Gavin
    Rammohan, Kottil
    Vermersch, Patrick
    Bock, Daena
    Hamlett, Anthony
    Fevr, Tea
    Musch, Bruno
    Greenberg, Steve
    NEUROLOGY, 2010, 74 (09) : A372 - A372
  • [2] Safety of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study
    Rammohan, K.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Kurukulasuriya, N.
    Bischof, D.
    Chang, P.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2011, 258 : 259 - 259
  • [3] Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study
    Rammohan, K.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Kurukulasuriya, N.
    Chang, P.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2011, 258 : 21 - 21
  • [4] Safety and Efficacy of Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis in Patients with High Disease Activity: Results from the Phase III, 96-Week CLARITY Study
    Rammohan, Kottil
    Comi, Giancarlo
    Cook, Stuart
    Giovannoni, Gavin
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Kurukulasuriya, Nuwan C.
    Chang, Peter
    Greenberg, Steven J.
    NEUROLOGY, 2011, 76 (09) : A612 - A613
  • [5] Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kurukulasuriya, Nuwan C.
    Greenberg, Steven J.
    Scaramozza, Matthew
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 123 - 136
  • [6] Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Vermersch, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. S.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Verjee, R.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S249 - S249
  • [7] Relapses and lymphocyte counts before and after rescue therapy in the phase III, 96-week, double-blind, placebo-controlled CLARITY study of cladribine tablets for relapsing-remitting multiple sclerosis
    Sorensen, P. Soelberg
    Giovannoni, G.
    Rieckmann, P.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Vermersch, P.
    Kurukulasuriya, N.
    Hamlett, A.
    Galazka, A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S411 - S411
  • [8] Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. S.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Viglietta, V.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S20 - S20
  • [9] Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. S.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Fevr, T.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S136 - S137
  • [10] Cladribine tablets produce sustained improvements in relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Rammohan, K.
    Vermersch, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rieckmann, P.
    Sorensen, P. S.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Verjee, R.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S249 - S249
12345